Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of “Hold” by Analysts

Bausch + Lomb Corporation (NYSE:BLCO) has earned an average recommendation of “Hold” from the thirteen brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $15.60.

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bausch + Lomb in a report on Saturday, September 27th. HC Wainwright increased their price objective on Bausch + Lomb from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Barclays decreased their price objective on Bausch + Lomb from $19.00 to $16.00 and set an “equal weight” rating for the company in a report on Monday, June 9th. Wells Fargo & Company increased their price objective on Bausch + Lomb from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Finally, Evercore ISI increased their price objective on Bausch + Lomb from $15.50 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th.

Hedge Funds Weigh In On Bausch + Lomb

Institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in shares of Bausch + Lomb by 428.7% during the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after acquiring an additional 242,993 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Bausch + Lomb during the first quarter valued at $4,712,000. Vident Advisory LLC bought a new position in shares of Bausch + Lomb during the first quarter valued at $289,000. Clearline Capital LP increased its holdings in shares of Bausch + Lomb by 38.2% during the first quarter. Clearline Capital LP now owns 893,790 shares of the company’s stock valued at $12,960,000 after acquiring an additional 247,149 shares in the last quarter. Finally, Nexpoint Asset Management L.P. increased its holdings in shares of Bausch + Lomb by 147.6% during the first quarter. Nexpoint Asset Management L.P. now owns 50,158 shares of the company’s stock valued at $727,000 after acquiring an additional 29,900 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Price Performance

Shares of Bausch + Lomb stock opened at $14.87 on Tuesday. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.76. The company has a market cap of $5.26 billion, a PE ratio of -19.06, a P/E/G ratio of 1.55 and a beta of 0.63. The business has a 50 day moving average of $14.63 and a 200 day moving average of $13.33. Bausch + Lomb has a 52 week low of $10.45 and a 52 week high of $21.69.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.25 billion. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Bausch + Lomb will post 0.74 earnings per share for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.